Pharmaceuticals company Cipla announced Q2FY26 results Income from Operations: Rs 7,589 crore compared to Rs 7,051 crore during Q2FY25, change 7.6%. EBITDA: Rs 1,895 crore compared to Rs 1,886 crore during Q2FY25, change 0.5%. EBITDA Margin: 25.0% for Q2FY26. PAT: Rs 1,351 crore compared to Rs 1,303 crore during Q2FY25, change 3.7%. Umang Vohra MD & Global CEO, Cipla, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY26, we delivered our highest-ever quarterly revenue of Rs 7,589 crore, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets. Our One-India business grew at 7% YoY. Key therapies in Branded Prescription business continued to deliver strong market growth and with the launch of Yurpeak® (Tirzepatide), we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly. Trade Generics recorded a double-digit growth and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of USD 233 million during the quarter. In Q3FY26, gRevlimid is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realized. In One Africa, we achieved a healthy growth of 5% YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front. “ Result PDF